Details for Patent: 10,617,695

Which drugs does patent 10,617,695 protect, and when does it expire?

Patent 10,617,695 protects LASTACAFT and is included in one NDA.

This patent has forty-six patent family members in thirty countries.

Summary for Patent: 10,617,695

Patent landscape, scope, and claims:

Title:	Ophthalmic compositions containing alcaftadine
Abstract:	Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof containing alcaftadine or a pharmaceutically acceptable salt thereof.
Inventor(s):	Ingerman; Avner (Bellmead, NJ), Janssens; Frans (Bonheiden, BE), Megens; Anton (Beerse, BE), Abelson; Mark B. (Andover, MA)
Assignee:	Vistakon Pharmaceuticals, LLC (Jacksonville, FL)
Application Number:	15/267,645
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 10,617,695

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	LASTACAFT	alcaftadine	SOLUTION/DROPS;OPHTHALMIC	022134-001	Jul 28, 2010		OTC	Yes	Yes	10,617,695		Y			USE OF LASTACAFT TO TEMPORARY RELIEVE ITCHY EYES DUE TO POLLEN, RAGWEED, GRASS, ANIMAL HAIR AND DANDER

International Family Members for US Patent 10,617,695

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	060278
Argentina	111697
Australia	2007234957